Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-12-04
2007-12-04
Allen, Marianne P. (Department: 1647)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C530S397000, C530S387300
Reexamination Certificate
active
09723955
ABSTRACT:
Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.
REFERENCES:
patent: 4397840 (1983-08-01), Takezawa et al.
patent: 4419446 (1983-12-01), Howley et al.
patent: 4667016 (1987-05-01), Lai et al.
patent: 4703008 (1987-10-01), Lin
patent: 5041376 (1991-08-01), Gething et al.
patent: 5217881 (1993-06-01), Park
patent: 5218092 (1993-06-01), Sasaki et al.
patent: 5378808 (1995-01-01), D'Andrea et al.
patent: 5480981 (1996-01-01), Goodwin et al.
patent: 5541158 (1996-07-01), Vance et al.
patent: 5661125 (1997-08-01), Strickland
patent: 5716644 (1998-02-01), Zale et al.
patent: 6340742 (2002-01-01), Burg et al.
patent: 6583272 (2003-06-01), Bailon
patent: 2002/0037841 (2002-03-01), Papadimitriou
patent: 2002/0115833 (2002-08-01), Burg et al.
patent: A 59145/90 (1991-01-01), None
patent: 2231192 (1998-03-01), None
patent: 2284910 (1999-09-01), None
patent: 0 148 605 (1985-07-01), None
patent: 0 267 678 (1988-05-01), None
patent: 0 357 804 (1990-03-01), None
patent: 0 370 205 (1990-05-01), None
patent: 0 428 267 (1991-05-01), None
patent: 0 640 619 (1995-03-01), None
patent: 0 640 619 (1997-07-01), None
patent: 2171303 (1986-08-01), None
patent: 2172303 (1986-08-01), None
patent: WO 89/03840 (1989-05-01), None
patent: WO 90/14363 (1990-11-01), None
patent: WO91/05867 (1991-05-01), None
patent: WO95/05465 (1995-02-01), None
patent: WO 99/02711 (1999-01-01), None
patent: WO99/11781 (1999-03-01), None
patent: WO 00/24893 (2000-05-01), None
patent: WO 00/61169 (2000-10-01), None
patent: WO 00/67769 (2000-11-01), None
patent: WO 00/67776 (2000-11-01), None
patent: WO 01/03737 (2001-01-01), None
Imai et al. Physicochemical and biological characterization of asialoerythropoietin. Suppressive effects on sialic acid in the expression of biological activity of human erythropoietin in vitro. European Journal of Biochemistry vol. 194:457-462 (1990).
Gross et al. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulation protein (NESP). The Journal of Biological Chemistry, vol. 281, No. 4:2024-2032 (2006).
Mitra et al. N-linked oligosaccharides as outfitter for glycoprotein folding, form and function. TRENDS in Biochemical Sciences. vol. 13, No. 3:156-163 (2006).
Broudy et al. Arch. Biochem. Biophys. 265, 329 (1988).
Cheng et. al., Proc. Natl. Acad. Sci. USA 91, 5695 (1994).
Cotes et al. Nature 191, 1065 (1961).
Cunningham et al. Science 244, 1081-1085 (1989).
DeLorme et al. Biochemistry 31, 9871-9876 (1992).
Dube et. al. J. Biol. Chem. 263, 17516 (1988).
Egrie et al. Glycoconjugate J. 10, 263 (1993).
Egrie et al,Blood, vol. 90, No. 10, Abstract 243-I, pp. 56a-57a (1997).
Elliott et al,Biochemistry,vol. 33, pp. 11237-11245 (1994).
Elliott et al Blood 87, 2714 (1996).
Eschbach et al. New Eng. J. Med. 316, 73-38 (1987).
Fibi et al,Blood, vol. 85, No. 5, pp. 1129-1236 (1995).
Fischl et al. New Eng. J. Med. 322, 1488-1493 (1990).
Gething et al.Nature 293, 620-625 (1981).
Higuchi, inPCR Protocolspp. 177-183 (Academic Press, 1990).
Kaufman et al. Mol Cell. Biol. 5, 1750-1759 (1985).
Komatsu et al., Blood 82, 456 (1993).
Lai et al.J. Biol. Chem. 261, 3116 (1986).
Laupacis, Lancet 341, 1228-1232 (1993).
Macdougall et al.,Journal of American Society of Nephrology, vol. 9, Abstract A1233, p. 268A (1997).
Miyake et al.J. Biol. Chem. 252, 5558 (1977).
Remington's Pharmaceutical Sciences, 18th ed. A.R. Gennaro, ed. Mack, Easton, PA (1980).
Syed et. al.Nature 395, 511 (1998).
Urlab et al.Proc. Natl. Acad. Sci. USA 77, 4216-4220 (1980).
Wells et al. Gene 34, 315-323 (1985).
Zoller et al. Meth. Enz. 100, 468-500 (1983).
Cheetham et al.,Nature Structural Biology,5(10):861-866 (1998).
Egrie et al.,British Journal of Cancer, 84:3-10 (2001).
U.S. Appl. No. 08/479,802, filed Jun. 6, 1995, Elliott et al.
Ashwell et al. “A Protein from Mammalian Liver That Specifically Binds Galactose Terminated Glycoproteins”,Methods Enyzmol.50, 287-288 (1978).
Boissel et al., “Erythropoietin Structure-Function Relationships”,The Biology of Hematopoiesis,pp. 227-232 (1990).
Boissel et al., “Erythropoietin Structure-Function Relationships”,J. Biol. Chem., 268, 15983-15993 (1993).
Bradford, Marion M., “A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding”,Anal. Biochem., 72, 248-254 (1976).
Briggs et al., “Hepatic Clearance of Intact and Desialylated Erythropoietin”,Am. J. Physiol., 227, 1385-1388 (1974).
Burbaum et al., “Understanding Structural Relationships in Proteins of Unsolved Three-Dimensional Structure”,Proteins,7(2), 99-111 (1990).
Burnette, Neal W., “Western Blotting: Electrophoretic Transfer of Proteins from Sodium Dodecyl Sulfate-Polyacrylamide Gels to Unmodified Nitrocellulose and Radiographic Detection with Antibody and Radioiodinated Protein A”,Anal. Biochem., 112, 195-203 (1981).
Chem et al., “Structural Role of Amino Acids 99-110 in Recombinant Human Erythropoietin”,Eur. J. Biochem., 202, 225-229 (1991).
Chou et al., “Prediction of the Secondary Structure of Proteins from their Amino Acid Sequence”,Adv. Enzymol., 47, 45-148 (1978).
Davis et al., “Characterization of Recombinant Human Erythropoietin Produced in Chinese Hamster Ovary Cells”,Biochemistry,26, 2633-2638 (1987).
Dorado et al., “Electrophoretic Behavior of Erythropoietin in Polyacrylamide Gel”,Biochem Medicine,6, 238-245 (1972).
Dordal et al., “The Role of Carbohydrate in Erythropoietin Action”,Endocrinology,116(6), 2293-2299 (1985).
Dube et al., “Glycosylation at Specific Sites of Erythropoietin is Essenmtial for Biosynthesis, Secretion, and Biological Function”,J. Biol. Chem263, 17516-17521 (1988).
Egrie et al., “Pharmacokinetics of Recombinant Human Erythropoietin (rHeEpo) Administered to Hemodialysis (HD) Patients”,Kidney Intl.,33, 262 (1988).
Egrie et al., “Characterization and Biological Effects of Recombinant Human Erythropoietin”,Immunobiology,172, 213-224 (1986).
Elliott et al., “An Immunological Approach to Determination of Protein Structure: Human Erythropoietin”,J. Cell. Biochem.Supp. 15G, Abstract No. R215 (1991).
Elliott et al., “Effect of Disulfide Bonds on the Structure and Activity of Erythropoietin”,J. Cell. Biochem.Supp. 17B, Abstract No. E318 (1993).
Elliott et al., “Structural Requirements for O-Linked Glycosylation of Human Erythropoietin”, Abstract of Presentation at Keystone Symposium, Mar. 21-27, (1992).
Elliott et al., “Structural Requirements for O-Linked Glycosylation of Human Erythropoietin”, Abstracts of the Protein Society, 5th Symp, Abstract No. M43 (1991).
Elliott et al., “Characterization of Anti Erythropoietin Monoclonal Antibodies”,Blood,74(Supp. 1), A 1228 (1989).
Elliott et al., “Secretion of glycosylated human erythropoietin from yeast directed by the α—factor leader region”,Gene79, 167-180 (1989).
Emini et al. “Induction of Hepatitis A Virus-Neutralizing Antibody by a Virus-Specific Synthetic Peptide,”J. Virology55(3):836-839 (1985).
Fu, et al., “The sheep erythropoietin gene: molecular cloning and effect of hemorrhage on plasma erythropoietin and renal/liver messenger RNA in adult sheep,”Molecular and Cellular Endocrinology93, 107-116 (1993).
Fuhr et al., “Evaluation of Commercial Erythropoietin Activity after Preparative Isoelec
Browne Jeffrey K.
Egrie Joan C.
Elliott Steven G.
Sitney Karen C.
Allen Marianne P.
Amgen Inc.
DeBerry Regina M.
Winter Robert B.
LandOfFree
Methods and compositions for the prevention and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the prevention and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the prevention and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3892551